Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079400918> ?p ?o ?g. }
- W2079400918 endingPage "300" @default.
- W2079400918 startingPage "293" @default.
- W2079400918 abstract "Several reports have appeared on the use of combined radioimmunotherapy (RAIT) and chemotherapy. The choice of drug to use with RAIT and how to space the two treatments has not been completely addressed. Because every patient's cancer presents with a specific molecular phenotype, we hypothesized that it may be necessary to tailor therapy based on specific gene expression. We addressed how the form of expression of a single gene, the p53 tumor suppressor, would impact the choice of agents, as well as sequence and spacing of agents. p53 regulates cell cycle arrest to allow for DNA repair after therapy-induced small DNA damage or induction of apoptosis if damage is great and has been shown to affect chemo- and radiosensitivity of cancer cells. We established 3 stable p53 transfectants of the SKOV-3 p53null parental line (p53(wt), p53(143mut) or p53(273mut)). p53 expression was confirmed using flow cytometry, using the DO1 pan-p53 Ab and the PAb240 anti-p53mut Ab. The colorimetric MTT assay was then used to measure dose-dependent growth inhibition from single modality chemotherapy (doxorubicin, carboplatin, paclitaxel or topotecan) or radioimmunotherapy (90Y-RS-7 IgG anti-EGP1). The % survival vs. log [drug] were plotted to obtain the IC50. We then used a matrix design in which we varied the sequence of the first and second modality of treatment and the spacing between the 2 treatments to determine the most synergistic and antagonistic combinations for the parental SKOV-3 and each of the 3 transfectants. The IC50 for each therapeutic agent varied as a function of the form of p53 expressed. For example, of the 4 lines, the p53wt transfectant was the most resistant to topotecan and the 143mut was the most resistant to carboplatin. The 273mut was quite sensitive to both doxorubicin and paclitaxel, whereas the p53null and wt were not. For multimodal treatments, most combinations of RAIT and chemotherapy resulted in a 30-40% growth inhibition (GI) and were either additive or moderately antagonistic. The 3 best (>60% GI) and 3 worst (<25% GI) combinations were identified and were unique to the parental p53null and to the 3 transfectants. Certain combinations showed clear synergy and others were antagonistic, with the first treatment modality blocking the growth inhibitory effects of the second treatment modality. The form of p53 expressed affects chemosensitivity and radiosensitivity and will influence optimal multimodal therapy with RAIT and chemotherapy and the dose-schedule (sequential with RAIT first or with drug first) when more than 1 agent is used." @default.
- W2079400918 created "2016-06-24" @default.
- W2079400918 creator A5003890903 @default.
- W2079400918 creator A5003932266 @default.
- W2079400918 creator A5018449749 @default.
- W2079400918 creator A5020155530 @default.
- W2079400918 creator A5051963794 @default.
- W2079400918 date "2003-01-01" @default.
- W2079400918 modified "2023-09-25" @default.
- W2079400918 title "Anin vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression" @default.
- W2079400918 cites W1566755443 @default.
- W2079400918 cites W1755920412 @default.
- W2079400918 cites W1973478663 @default.
- W2079400918 cites W1983914017 @default.
- W2079400918 cites W2004804291 @default.
- W2079400918 cites W2006870947 @default.
- W2079400918 cites W2011498701 @default.
- W2079400918 cites W2012773270 @default.
- W2079400918 cites W2014222939 @default.
- W2079400918 cites W2018209489 @default.
- W2079400918 cites W2018295066 @default.
- W2079400918 cites W2024487324 @default.
- W2079400918 cites W2035931538 @default.
- W2079400918 cites W2038809726 @default.
- W2079400918 cites W2046424185 @default.
- W2079400918 cites W2057743303 @default.
- W2079400918 cites W2060519872 @default.
- W2079400918 cites W2066341828 @default.
- W2079400918 cites W2074580909 @default.
- W2079400918 cites W2078860796 @default.
- W2079400918 cites W2081894694 @default.
- W2079400918 cites W2083365094 @default.
- W2079400918 cites W2085594308 @default.
- W2079400918 cites W2096745279 @default.
- W2079400918 cites W2102744264 @default.
- W2079400918 cites W2106012381 @default.
- W2079400918 cites W2114918609 @default.
- W2079400918 cites W2131450855 @default.
- W2079400918 cites W2132979902 @default.
- W2079400918 cites W2140894046 @default.
- W2079400918 cites W2162522735 @default.
- W2079400918 cites W2163825909 @default.
- W2079400918 cites W2331254803 @default.
- W2079400918 cites W295334282 @default.
- W2079400918 doi "https://doi.org/10.1002/ijc.11534" @default.
- W2079400918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14639618" @default.
- W2079400918 hasPublicationYear "2003" @default.
- W2079400918 type Work @default.
- W2079400918 sameAs 2079400918 @default.
- W2079400918 citedByCount "17" @default.
- W2079400918 countsByYear W20794009182012 @default.
- W2079400918 countsByYear W20794009182013 @default.
- W2079400918 countsByYear W20794009182016 @default.
- W2079400918 crossrefType "journal-article" @default.
- W2079400918 hasAuthorship W2079400918A5003890903 @default.
- W2079400918 hasAuthorship W2079400918A5003932266 @default.
- W2079400918 hasAuthorship W2079400918A5018449749 @default.
- W2079400918 hasAuthorship W2079400918A5020155530 @default.
- W2079400918 hasAuthorship W2079400918A5051963794 @default.
- W2079400918 hasBestOaLocation W20794009181 @default.
- W2079400918 hasConcept C121608353 @default.
- W2079400918 hasConcept C126322002 @default.
- W2079400918 hasConcept C143425029 @default.
- W2079400918 hasConcept C143998085 @default.
- W2079400918 hasConcept C159654299 @default.
- W2079400918 hasConcept C203014093 @default.
- W2079400918 hasConcept C2776146153 @default.
- W2079400918 hasConcept C2776694085 @default.
- W2079400918 hasConcept C2777292972 @default.
- W2079400918 hasConcept C2778239845 @default.
- W2079400918 hasConcept C2781209748 @default.
- W2079400918 hasConcept C2781303535 @default.
- W2079400918 hasConcept C2781451048 @default.
- W2079400918 hasConcept C29537977 @default.
- W2079400918 hasConcept C502942594 @default.
- W2079400918 hasConcept C542903549 @default.
- W2079400918 hasConcept C54355233 @default.
- W2079400918 hasConcept C552990157 @default.
- W2079400918 hasConcept C553184892 @default.
- W2079400918 hasConcept C71924100 @default.
- W2079400918 hasConcept C86803240 @default.
- W2079400918 hasConceptScore W2079400918C121608353 @default.
- W2079400918 hasConceptScore W2079400918C126322002 @default.
- W2079400918 hasConceptScore W2079400918C143425029 @default.
- W2079400918 hasConceptScore W2079400918C143998085 @default.
- W2079400918 hasConceptScore W2079400918C159654299 @default.
- W2079400918 hasConceptScore W2079400918C203014093 @default.
- W2079400918 hasConceptScore W2079400918C2776146153 @default.
- W2079400918 hasConceptScore W2079400918C2776694085 @default.
- W2079400918 hasConceptScore W2079400918C2777292972 @default.
- W2079400918 hasConceptScore W2079400918C2778239845 @default.
- W2079400918 hasConceptScore W2079400918C2781209748 @default.
- W2079400918 hasConceptScore W2079400918C2781303535 @default.
- W2079400918 hasConceptScore W2079400918C2781451048 @default.
- W2079400918 hasConceptScore W2079400918C29537977 @default.
- W2079400918 hasConceptScore W2079400918C502942594 @default.
- W2079400918 hasConceptScore W2079400918C542903549 @default.
- W2079400918 hasConceptScore W2079400918C54355233 @default.